Phax: A Rapid Cell-Free Phage Discovery Platform for Scalable Personalised Antimicrobial Therapies

Phage therapy is an essential strategy to mitigate the impact of antibiotic-resistance, and the Katana Bioworks Phax platform will enable scalable phage therapy by reducing costs and lead-time.

While phage therapy is safe and effective, broad adoption/application is limited by the lead-time to identify then manufacture phage (median 171 days).

Phax is a rapid lead-to-hit phage discovery workflow pairing _in silico_ phage prediction and cell-free bacteriophage synthesis (CFBS) to engineer personalised phage therapy on-demand.